GREAT-WALL-MOTOR
5.6.2019 11:19:08 CEST | Business Wire | Press release
At 12:06 on June 5, 2019, CZ-11 Solid-fuel Space Launch Vehicle (CZ-11 WEY) sees its first sea launch on the Yellow Sea, successfully sending seven satellites into the preset orbit and ushering in a new era of CASC development. The leading Chinese luxury SUV brand WEY is the first business partner of CASC. Both parties jointly call this launch vehicle as “CZ-11 WEY”, which marks a new breakthrough in business model of CASC. In addition, the Joint Technology Innovation Center co-initiated by CASC and WEY aims to put technologies into practice in the fields of quality system and testing, autonomous driving technology, new materials application and hydrogen energy through steady progress, so that the aero technology can be readily available.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005423/en/
CZ-11 Space Launch Vehicle is the first and only type of solid-fuel launch vehicles in the CZ Launch Vehicle Family. It is nearly 21 meters long and 58 tons weigh. Boasting a take-off thrust of 120 tons, it can carry up to 500 kg of payloads into the sun-synchronous orbit at a height of 500 km. This sea launch of CZ-11 WEY crystallizes the breakthroughs in a number of key technologies, such as wireless remote control at the front and rear terminals, independent intelligent security control on launcher, aiming of mobile base launching on the sea. CZ-11 Space Launch Vehicle has not only achieved China’s first-ever sea launch and low-inclination launch, but also created a new launch mode for Chinese launch vehicles into the space.
In conjunction with this sea launch, CASC and WEY steadily advance technical exchanges and cooperation in two fields. Both parties will promote integration in four fields of quality system and testing, autonomous driving technology, new materials application and hydrogen energy. They are committed to strongly empowering the independent R&D and manufacturing and creating greater market opportunities and economic value for CASC. Moreover, through technology application in the automotive industry, the aerospace technology can be readily available.
It is worth mentioning that Creative Experience Activity of “Dialogue with Parallel Universe” is jointly held by WEY and CASC. Through digital transmitter mounted on CZ-11 WEY Satellite, the voices of many consumers are transmitted to the outer space in the form of electric wave to “dialogue across the space” with another themselves in parallel universe. Compared with the international program of “Send Your Name to Mars with NASA’s next Mars Rover”, this sea launch is such a magnificent feat that retains the peoples’ voices and names in the space earlier.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005423/en/
Contact:
Great Wall Motor Liu Jian +8618241766066 liujian@dsconsulting.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom